Background: Our previous study indicated that soy protein with isoflavones lessened lumbar spine bone loss in midlife women.
Objective: We examined the efficacy of isoflavones (extracted from soy protein) on bone mineral density (BMD) in nonosteoporotic postmenopausal women. We hypothesized that isoflavone tablets would spare BMD, with biological (age, body weight, serum 25-hydroxyvitamin D) and lifestyle (physical activity, dietary intake) factors modulating BMD loss.
Design: Our double-blind, randomized controlled trial (36 mo) included healthy postmenopausal women (aged 45.8-65.0 y) with intent-to-treat (n = 224) and compliant (n = 208) analyses. Treatment groups consisted of a placebo control group and 2 soy isoflavone groups (80 compared with 120 mg/d); women received 500 mg calcium and 600 IU vitamin D(3). Outcomes included lumbar spine, total proximal femur, femoral neck, and whole-body BMD.
Results: Analysis of variance for intent-to-treat and compliant (> or =80%) models, respectively, showed no treatment effect for spine (P = 0.46, P = 0.21), femur (P = 0.86, P = 0.46), neck (P = 0.17, P = 0.14), or whole-body (P = 0.86, P = 0.78) BMD. From baseline to 36 mo, BMD declined regardless of treatment. In intent-to-treat and compliant models, respectively, BMD decreases were as follows: spine (-2.08%, -1.99%), femur (-1.43%, -1.38%), neck (-2.56%, -2.51%), and whole body (-1.66%, -1.62%). Regression analysis (compliant model) indicated that age, whole-body fat mass, and bone resorption were common predictors of BMD change. After adjustment for these factors, 120 mg (compared with placebo) was protective (P = 0.024) for neck BMD. We observed no treatment effect on adverse events, endometrial thickness, or bone markers.
Conclusion: Our results do not show a bone-sparing effect of extracted soy isoflavones, except for a modest effect at the femoral neck. This trial was registered at clinicaltrials.gov as NCT00043745.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793109 | PMC |
| http://dx.doi.org/10.3945/ajcn.2009.28306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
Mult Scler
January 2025
Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Spinal cord (SC) atrophy is a key imaging biomarker of progressive multiple sclerosis (MS). Progressive MS is more common in men and postmenopausal women.
Objective: Investigate the impact of sex and menopause on SC measurements in persons with MS (pwMS).
Association between physical activity and cognitive function in post-menopausal women with high parity: the chain-mediating effects of nutritional status and depression.
BMC Womens Health
January 2025
Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Background: It has been reported that the cognitive responses to physical activity (PA) in postmenopausal women vary by parity status, and women with higher parity show a significant association between PA and cognitive function. However, the potential pathways mediating the relationship between PA and cognitive function in women with higher parity remain unclear. The objective of this study was to examine this association in Chinese cohort and further investigate the mediating pathways.
View Article and Find Full Text PDFThe effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with rheumatoid arthritis: a randomized controlled trial.
Sci Rep
January 2025
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran.
Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting postmenopausal women. This study investigated the effects of intermittent fasting (IF) on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with RA. This 8-week randomized controlled trial included 44 postmenopausal women with RA divided into an intervention group following a 16:8 IF diet and a control group maintaining their usual diet and received recommendations for healthy eating.
View Article and Find Full Text PDFFrontal Fibrosing Alopecia (FFA) Part I - Diagnosis and Clinical Presentation.
J Am Acad Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL.
Frontal Fibrosing Alopecia (FFA) is a primary lymphocytic cicatricial alopecia predominantly affecting postmenopausal Caucasian women. It is characterized by a progressive frontotemporal hairline recession that presents as a scarring hairless band and is often accompanied by eyebrow and body hair loss. Although initially described in postmenopausal women, FFA has been observed in a broader demographic, including premenopausal women and occasionally men.
View Article and Find Full Text PDFSexual function after treatment with non-invasive radiofrequency device for improvement of the genitourinary syndrome of menopause: A multi-arm randomized clinical trial.
Eur J Obstet Gynecol Reprod Biol
January 2025
Department of Obstetrics and Gynecology of Faculty of Medical Sciences, State University of Campinas (FCM-UNICAMP), Campinas, SP, Brazil. Electronic address:
Background: Several anatomical and functional changes occur during menopause and lead to female sexual dysfunction (FSD). The use of energy-based devices to improve women's sexual health brings an innovative scenario.
Aim: To evaluate the effect of non-invasive radiofrequency (RF) treatment compared to vaginal estrogen therapy (E) and vaginal moisturizer (M) in postmenopausal women with FSD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!